GENMAB på Børsen Play efter Q3
-
"Genmab opjusterer forventningerne".
Nordea: "Der er forsat potentiale i Genmab".
Genmabchef: "Vi vil gå over i historien med Daratumumab".
Storinvestor: "Prisen på Genmab er urealistisk lav".
Kjærgaard: "Skynd dig at hoppe på Genmabtoget".
Redaktør: "Det kan være svært at se, hvad der kan få Genmab-aktien ned".
Nordea: "Risikoen og potentialet er stor i Genmab".
-
Fornuftige overvejelser omkring Fingerprint Cards prissætning fra Christian Kjærgaard:
-
Teknisk analyse på Genmab på Børsen Play:
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind